澳大利亚HealthLinx  
HealthLinx是对重点发展的新型血液中有未满足市场需求，有针对性的疾病诊断的生物标志物和诊断开发公司。

卵巢癌的计划已在2008年完成第二阶段的生物标志物的试验，筛选出150患病样本和正常样本212结果与发展OvPlex的™卵巢癌的诊断，针对症状的妇女。从多国多中心试验的中期结果，在2011年底公布的市场，有超过740的样本，在一个全球性的招聘活动，涉及在澳大利亚，新加坡和英国的医生使用。 HealthLinx平台套件是面向快速识别，开发和验证生物标志物诊断中的应用，以及保健品和治疗线索。虽然平台是适用于各种各样的疾病迹象，HealthLinx最初集中在卵巢癌。

HealthLinx’s suite of platforms is oriented towards the rapid identification, development and validation of biomarkers for diagnostic application as well as nutraceutical and therapeutic leads. Although the platforms are applicable to a wide variety of disease indications, HealthLinx has focused initially on ovarian cancer.

The company’s business model is to develop multi marker diagnostics for disease indications that have un-met market needs to a phase II biomarker trial achieving statistical significant results and releasing the products in the Australian market. Now that the product has been launched in Australia, the company is developing partnerships with distributors in other jurisdictions who will complete all regulatory requirements for mass distribution of OvPlex™. The company is also seeking to collaborate with research groups and clinical trial groups to use the assays as surrogate markers in clinical trials and research programs. This will allow for the capture of additional independent data to further validate the panels and generate revenue.